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A new synthetic retinoid analogue, adapalene (6-[3-(1-ada-
mantyl)-4-methoxyphenyl]-2-naphthoic acid, CD271), 
which is relatively selective for retinoic acid receptor fl, was 
noted to be an effective comedolytic agent in the rhino mouse 
model and to have clinical efficacy against acne. In pursuit of 
this observation, we studied the effects of CD271 on the 
development of erythema, spongiosis, and epidermal hyper-
plasia as well as other well-characterized markers of in vivo 
retinoid action after 4 d of occluded topical treatment. The 
objective of the study was to elucidate further those parame-
ters associated with potential clinical efficacy. Twenty-five 
subjects were treated with 0.1 % all-trans retinoic acid cream, 
all-trans retinoic acid vehicle, 0.1 % CD271 gel, or CD271 
vehicle under occlusion for 4 d. 
Only all-trans retinoic acid induced erythema (p < 0.01 
versus all other treatments). Similarly, histologic analysis re-
vealed that epidermal hyperplasia and spongiosis were in-
duced only by all-trans retinoic acid (p < 0.01 versus all other 
T opical all-trailS retinoic acid (RA) and other retinoids elicit an increasingly well-characterized series of clin-ical, histologic, cellular, and molecular responses when administered systemically or applied topically to human skin [1 -4]. A similar spectrum of activ-
ities is observed after RA treatment of skin-equivalent cultures 
[5], demonstrating that retinoids are capable of profound and di-
rect modulation of the intrinsic program of epidermal differentia-
tion. Adapalene (6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naph-
thoic acid, CD271) displays potent retinoid activity in several 
ill vitro and ill vivo assays [6,7]' and shows relative selectivity 
for retinoic acid receptor fJ (RAR-fJ) and to a lesser extent 
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~re~tme~ts). By immunohistochemical analysis: all-trans ret-
1ll01~ aCId m~reased expression of epidermal transglutamin-
ase, lI1volucnn, and calgranulin (p < 0.05 versus all other 
treatments). In contrast to these data, both CD271 and all-
trans r.etinoic acid caused marked and significant (p < 0.05) 
elevatlOn of cellular retinoic acid - binding protein-II 
(CRABP-II) messenger ribonucleic acid steady-state levels as 
judged by q~antitative RNA blot analysis. Although CD271 
treatment. dId ~<?t lea~ to erythema or affect epidermal mor-
phology, Its ablhty to mduce a marker of retinoid action (i.e., 
C~P-II) was 70% the potency of all-trans retinoic acid. 
ThIS study s~~ge~ts ~hat CRABP-II gene expression may 
be. a more senSItIve l11dlcator of retinoid biologic activity in 
skl11 t?an are .erythema or changes in epidermal morphology 
and dlfferentlatlOn. 
Key words: epidermal hyperplasia/spongiosis/transgluta-
minase/calgranulin. ] I,west Dermato11 01 :325 - 328, 1993 
RAR-y [8]. In recent clinical studies, CD271 0.1 % gel was shown 
to be as effective as 0.025% RA gel in the treatment of comedonal 
acne [9]. 
~urine and i~ vitro .models of retinoid activity can supply infor-
matlOn that, at tllnes, IS paradOXical to observations made ill vivo in 
humans [10]. As a result of this conflict we have developed an ill villo 
human assay for epidermal retinoid activity that entails 4-d occlu-
sion of the retinoid under study on the buttock skin of normal 
volunt~er~ [1] .. Changes in epider.mal morphology produced by RA 
(sponglOsls, el?ldermal hyperpla~la, and thickening of the granular 
layer) at 4 d m thiS assay are Similar to observations made after 
long-term clinical treatment [3 ,4]. Markers of differentiation and 
proliferation, such as epidermal trans glutaminase and involucrin, 
a:e also induced by RA in this assay, again correlating with observa-
tl.ons. made after long-term treatment [2,11]. Cellular retinoic acid-
b111d111g protem-II . (CRABP-II) ribonucleic acid, messenger 
(mRNA). IS const1tu.t1Ve~y e~pr~ssed in human and murine skin [12-
14J but ItS expreSSlOn IS slgn.Ificantly enhanced after topical RA 
treatment [5,1~]. CR!ill~-II I~ an early, specific, highly sensitive 
marker of topical ret1110!d activity, not merely associated with a 
hyperproliferative state [15]. 
In this study we have used a 4-d bioassay to compare the effects of 
0.1 % CD271 gel and 0.1 % RA cream on erythema, epidermal mor-
phology, markers of differentiation and CRABP-II mRNA expres-
sion. 
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Table I. Comparison of Epidermal Histology Following 4-day Occlusive Treatment" 
RA vehicle 0.1% RA CD271 vehicle 0.1 % CD271 
Histologic parameterl' (n = 9) (n = 9) (n = 9) (n=9) 
Stratum corneum compaction 1.7 ± 0.4' 2.7 ± 0.4' 0.7 ± 0.3J 0.6 ± 0.2J 
Granular layer thickness 0.7 ± 0.2' 2.0 ±O.Y 0.2 ± 0.1 ' 0.6 ± 0.1' 
Spongiosis 1.5 ± 0.3' 2.5 ± 0.2J 1.1 ± 0.3' 0.9 ± 0.3' 
Mitoses/5 HPF 0.2 ± 0.2' 2.2 ± 0.7J 0.3 ± 0.2' 0.2 ± 0.2' 
Epidermal thickness (urn) 61 ± 6' 100 ± 7J 53 ± 7' 51 ± 6' 
, All values arc mean ± SEM . 
• Except for epidermal thickness and mitotic figures, all parameters arc scored on a 0 to 4 scale. 
, ,d.< For each parameter, pairwise comparison of means with at least one superscript in common denotes non-significant differences at the 0.05 level. 
MATERIALS AND METHODS 
Normal volunteers (all of whom had given written consent in a protocol 
approved by the University of Michigan Medical Center Institutional Re-
view Board) had the four test agents applied to buttock skin (ISO mgs/9 cm2) 
according to a computer-generated randomization code, and the sites oc-
cluded under Saran Wrap for 4 d. The test agents applied were 0.1 % RA 
cream, RA vehicle cream (Ortho Pharmaceutical Corporation, Raritan, NJ) , 
0.1 % CD271 aqueous gel suspension, and CD271 gel vehicle (Owen Gal-
derma, Fort Worth, TX). 
After 4 d, the occlusive patch was removed and the degree of erythema 
present at each test site scored according to a 1 O-point scale where 0 is none; 
1-3, mild; 4-6, moderate, and 7-9, severe. Keratomes and 6-mm punch 
biopsies were performed under 1 % plain lidocaine anesthesia. 
In 10 subjects, two 6-mm punch biopsies were taken from each test site. 
One biopsy was placed in 10% neutral-buffered formalin and processed for 
hematoxylin and eosin histology and the other biopsy frozen in liquid nitro-
gen and stored at -70°C until used for immunohistochemical analysis. In 
eight subjects, a keratome biopsy (0.2 mm in depth) was taken from each 
treatment site, immediately snap-frozen in liquid nitrogen and stored at 
-70°C until used for RNA isolation. 
Histology Biopsies processed to hematoxylin and eosin were read at the 
light microscope level by one investigator (LJF) who was blinded to which 
treatment group the specimen had come from. Stratum corneum compac-
tion, spongiosis, and granular layer thickness were assessed using a 0 to 4 
ordinal scale where 0 = none and 4 = maximum. Epidermal thickness mea-
sured in micrometers from the base of the stratum corneum to the basement 
membrane was assessed in five high power fields and the mean thickness 
used. Mitotic figures were counted per five high-power fields. 
Immunohistochemistry Indirect immunofluorescence on 5-Jlm frozen 
sections was performed as previously described [16] using the following 
antibodies: F12 monoclonal antibody to calgranulin [17,18] and B.Cl 
monoclonal antibody to human transglutaminase [19] (generous gifts of 
Professor L. Juhlin, Uppsala, Sweden and Dr. S. Thacher, Texas A & M 
University, College Station, TX, respectively); mouse monoclonal antibody 
to human keratin 10 (RKSE60, Sanbio Laboratories, Netherlands) and rabbit 
polyclonal antibody to human involucrin {Biomedical Technologies, Inc. , 
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Figure 1. Epidermal thickness of 4-d occlusive treatment of normal skin 
with 0.1 % RA cream, RA vehicle, 0.1 % CD271 gel, or CD271 gel vehicle. 
RA produced significant (p < 0.01) epidermal hyperplasia as compared with 
the other three treatment, which were not significantly different from one 
another. All va lues mean ± SEM; n = 9. 
Stoughton, MA). A polyclonal antiserum to loricrin was obtained by im-
munizing a rabbit with a loricrin carboxy terminal peptide [20]. Fluorescein 
and rhodamine conjugates were purchased from Nordic, Netherlands. 
Quantification of immunohistochemical staining reactions was as fol-
lows. For epidermal transglutaminase, involucrin, calgranulin, and loricrin, 
the number of epidermal cell layers staining for each marker was counted. In 
the case of keratin 10, the staining pattern was assessed as 0, strictly supraba-
sal; I, minimum focal reduction; and 2, maximum focal reduction. 
RNA Isolation and Northern Blot Analysis Total RNA was isolated 
from snap-frozen keratome biopsies using the guanidinium-cesium chloride 
procedure as previously described [21], except that cesium trifluoroacetate 
(Pharmacia, Piscataway, NJ) was substituted for cesium chloride according 
to the manufacturer's instructions. Forty micrograms total RNA (deter-
mined by absorbance at 260 nm) was fractionated by electrophoresis over 
1 % formaldehyde-agarose gels and transferred to derivatized nylon mem-
brane (Zeta-Probe, Bio-Rad, Richmond, CA). Blots were sequentially hy-
bridized against 32P-labeled CRABP-ll and cyclophilin probes prepared by 
random priming and quantitated using a phosphorimager (Molecular Dy-
namics) as previously described [12] . Hybridization to the CRABP-II probe 
was normalized to cyclophilin and results for each patient expressed as 
number of times change relative to CD271 vehicle. I 
Statistical Methods Treatment group comparisons were assessed with a 
repeated measures analysis of variance and the Tukey multiple comparison 
test. Two-sided significance was determined at the 0.05 and 0.01 type I error 
rates. Summary data arc represented as means ± SEM. The analyses were 
performed by BMDP statistica l software. 
RESULTS 
Clinical Only RA induced erythema (score of 4.8 ± 0.3) and this 
was significantly more than CD271 (score of 0.3 ± 1) and all other 
treatments (p < 0.01; n = 25). 
Histology RA increased epidermal hyperpl asia (100 11m ± 7) as 
compared with RA vehicle (61 11m ± 6) and CD271 vehicle 
(53 11m ± 7) (see Table 1; n = 9 for all parameters). No epidermal 
hyperplasia was induced by CD271 (51 11m ± 6), and this was sig-
nificantly less than RA (p < 0.01, Fig 1). Spongiosis was also signif-
icantly increased by RA (2 .5 ± 0.2) as compared with CD271 
(0.9 ± 0 .3, P < 0.01). 
Immunohistochemistry As previously observed in this bioassay 
system, the number of epidermal cell layers expressing epidermal 
transglutaminase was considerably increased following RA treat-
ment (9.9 ± 1.0) as compared with vehicle (2.2 ± 0 .2, P < 0.01 ) 
(see Table II; n = 10 for all parameters). Treatment with CD271 
produced no expansion of epidermal trans glutaminase staining and 
was not significantly different from vehicle. Both calgranulin and 
involucrin expressions were also enhanced by RA and these were 
significantly greater than CD271 (p < 0 .01). Keratin 10 was fo-
cally reduced by RA as compared with a strictly suprabasal expres-
sion in vehicle-treated epidermis (p < 0.05), CD271 produced 
some reduction in keratin 10 expression but this was not signifi-
cantly different from either vehicle. Loricrin expression was not 
significantly altered by any of the treatments. 
CRABP-II mRNA The results of Northern blot analysis of tis-
sue from two representative volunteers are shown in Fig 2 and data 
for the eight subjects studied are summarized in Fig 3. Although 
some variability in response to CD271 and RA vehicles was noted 
(compare lift and right palle/s, Fig 2), a consistent, marked and signif-
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Table II. Effects of 4-Day Occlusive Treatment on Markers of Differentiationa 
RA vehicle 0.1% RA C0271 vehicle 0.1% C0271 
Marker" (n = 10) (n = 10) (n = 10) (n= 10) 
Keratin 10 
Transglutaminase 
Involucrin 
Loricrin 
Calgranulin 
0.3±0.1' 1.0 ± 0.2J 0.1±0.1' 0.4 ± 0.2"J 
2.2 ± 0.2' 9.9 ± 1.0J 1.9±0.1' 2.1 ± 0.2' 
4.2 ± 0.4' 13.0 ± 0.6J 3.0 ± 0.2' 3.4 ± 0.2' 
2.4 ± 0.5' 2.5 ± 0.6' 3.1 ± 0.4' 2.9 ± 0.3' 
0.3 ± 0.2' 6.1 ± l.l J 0.0 ± 0.0' 0.2 ± 0.1' 
• Ail values arc mean ± SEM. 
; Keratin to is scored on a 0 to 2 scale (see Materials "lid Methods); all other values represent number of epidermal cell layers expressing the marker in question. 
,.J" For each marker. pairwise comparison of means with at least one superscript in cOl)1mon denotes non-significant differences at the 0.05 level. 
icant induction of CRABP-II mRNA was noted in response to RA 
and CD271 relative to either vehicle (p < 0.05, Fig 3). CD271 
increased CRABP-II mRNA to 70% of the levels observed with 
RA, By contrast, erythema and histologic effects were seen only 
with RA, CD271 and both vehicles having no significant effect. 
DISCUSSION 
This study demonstrates that CD271 is capable of inducing 
CRABP-Il mRNA in the absence of changes in epidermal mor-
phology. These findings contrast with the concord~nce obse~ed 
between epidermal changes and CRABP-I1 expressIOn followmg 
the administration of 0.1 % RA cream. 
The induction of epidermal hyperplasia and spongiosis, coupled 
with enhanced expression of epidermal transglutaminase and invo-
lucrin are in agreement with previous data using 0.1 % RA cream in 
the 4-d assay [1,10,11]. However, it is unknown why RA focally 
inhibited keratin 10 and had no effect on loricrin expression in this 
study, whereas keratin 10 wa~ u.naffe.cted and loricrin. inhib!te~ in 
previous work [11]. Calgranuhn IS an.ll1tracellular, ~alclUm-~mdll1.g 
protein absent from normal e£ldermls but present m the epidermis 
of inflammatory dermatoses [22]; the presence of calgranulin may 
be independent of keratinocyte proliferation [23]. In this study, 
calgranulin expression was significantly enhanced in RA-treated 
epidermis; the exact nature of this enhancement is unknown but 
probably relates to keratinocyte hyperproliferation in this case [17]. 
Overall , these short-term events under occlusion are predictive of 
epidermal changes in long-term, unoccluded, RA-treated skin [11]. 
Although CD271 0.1 % gel possesses retinoid activity in the rhino 
mouse model , as evidenced by epidermal hyperplasia and comedo-
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Figure 2. Northern blot ofCRABP-II response to 4-d occlusive application 
of 0.1 % RA cream versus 0.1 % CD271 gel and respective vehicles. Results 
shown are from two representative patients in that they reflect the largest 
differences in signal observed over vehicle controls. Note that independent 
of the response to vehicle, CRABP-II is induced by both 0.1 % RA and 0.1 % 
C027!. Sizes of bands (in kb) are indicated to the left and probes used, 
CRABP-II and cyclophilin (cyclo), to the right. 
lysis [6,7), this .does not appear to be the case using the 4-d human 
a~say. It IS pOSSIble that the discrepancy between assay systems may 
sl~ply b~ one <?f gre~ter penetration of CD271 through relatively 
thm m~rme epiderrrus, thereby resulting in higher epidermal con-
centrations of the drug than could be obtained in human skin. How-
ever, the observed induction of CRABP-II gene expression by 
CD271, up to 70% of that seen with 0.1 % RA cream, argues for 
penetrance of small amounts of CD271 under these conditions. We 
have previously observed that elevated CRABP-I1 levels are a 
highly sen~itive marker o.f retinoid activity [15]. Indeed, RA at a 
~oncentratlOn of 0.001 % 111 ethanol/propylene glycol vehicle will 
~ndu~e CRAB~-II expression in the absence of significant changes 
111 epI?ermal histology (Griffiths CEM, Elder JT, unpublished ob-
servatlons) . 
CD27! ~elongs to a ne~ ~lass of synthetic retinoic acid analogues 
that exhibit some selectiVity for certain RARs. In the case of 
CD2~1,.the relati~e selectivity is for RAR-P [8], a receptor that in 
the skin IS predorrunantly expressed in dermis, and to a lesser extent 
RAR-y [8], ~hich is mainly expressed in epidermis [5]. Although 
we have prevIOusly discounted any direct role in CRABP-II in the 
biolo~ic action of CD271 [24] it is of interest to note that the gene 
encodll1g CRABP-II contains a retinoic acid response element in 
the promoter region that is transactivated by both RAR-p and RAR-
y [?5]. CRABP-II appears to regulate the bioavailability of RA by 
actll1g as both a trap for RA and a cofactor in its metabolic oxidation 
[26] . In view of their distinct structural differences, it is unlikely 
that CD271 would undergo the same catabolic oxidation as RA. 
However, we cannot rule out that CD271 could be metabolized in 
the viable epidermis (demethylation for example) and that CRABP-
II plays an indirect role in that process. 
Re£orts of the efficacy of 0.1 % CD271 gel in the treatment of 
acne,l9] indicat~ th~t the rhino mouse model of comedolysis can be a 
predictor of retll10ld efficacy for acne therapy. Whether changes in 
Figure 3. Quantitative analysis of Northern blots. Relative times increase 
in CRABP-Il mRNA (relative to C0271 vehicle) following 4-d occlusive 
treatment of normal skin using 0.1 % C0271 gel. 0.1 % RA cream and RA 
vehicle. Both CD271 and RA produced a significant increase (p < 0,05) in 
CRABP-II mRNA levels relative to vehicle. All values are mean ± SEM; 
n=8. 
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differentiation markers and epidermal hyperplasia in RA-treated 
skin are indicative of a therapeutic effect in acne and/or photoda-
mage or are side effects is a point of considerable interest. Experi-
ments performed in this assay with the irritant sodium lauryl sulfate 
indicate that, although an irritant will induce changes in epidermal 
morphology and markers of differentiation very similar to those 
produced by RA, the irritant does not elevate CRABP-II levels [15] . 
In conclusion, the 4-d human assay demonstrates that CD271, in 
a formulation known to be therapeutic in acne, does not induce the 
epidermal changes associated with retinoid activity but does elevate 
epidermal CRABP-ll mRNA. The study underscores the sensitivity 
and specificity of CRABP-II elevation in response to topical reti-
noids whether it be a non-specific receptor agonist, such as RA, or a 
more selective agonist, as in the case of CD271. However, it still 
remains to be shown whether the ability to elevate CRABP-ll 
mRNA can be a predictor of a retinoid's clinical efficacy. 
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